SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 45 filers reported holding SYROS PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $2,667,000 | -29.3% | 274,074 | +7.0% | 0.65% | -39.1% |
| Q3 2017 | $3,771,000 | +28.7% | 256,215 | +40.7% | 1.06% | -1.8% |
| Q2 2017 | $2,931,000 | +1.0% | 182,141 | 0.0% | 1.08% | -36.7% |
| Q1 2017 | $2,902,000 | +31.0% | 182,141 | 0.0% | 1.71% | -6.4% |
| Q4 2016 | $2,215,000 | +219.2% | 182,141 | +264.3% | 1.83% | +225.4% |
| Q3 2016 | $694,000 | -23.6% | 50,000 | 0.0% | 0.56% | -37.8% |
| Q2 2016 | $908,000 | – | 50,000 | – | 0.90% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 200,000 | $1,768,000 | 8.83% |
| Samsara BioCapital, LLC | 1,407,949 | $11,608,000 | 3.24% |
| Flagship Pioneering Inc. | 2,938,494 | $25,976,000 | 0.72% |
| ARK Investment Management | 11,212,506 | $99,119,000 | 0.59% |
| Portolan Capital Management | 450,861 | $3,986,000 | 0.45% |
| Capital Impact Advisors, LLC | 168,600 | $1,490,000 | 0.44% |
| Nikko Asset Management Americas, Inc. | 4,182,346 | $36,261,000 | 0.32% |
| Sio Capital Management, LLC | 166,780 | $1,474,000 | 0.29% |
| Virtus ETF Advisers LLC | 34,835 | $308,000 | 0.16% |
| Artal Group S.A. | 465,500 | $4,115,000 | 0.10% |